Table 2.

Baseline characteristics of treatment groups

Treatment Group		SRI baseline	SRI Dose baseline (mg/day)	Previous SRI trials	Total YBOCS – Baseline	Total YBOCS – Week 6	Endpoint dose (mg/day)	% CHANGE	CGI – Improvement	Response status
Quetiapine	1	Paroxetine	60	1	33	29	50	-12.00	3	N/R
	2	Citalopram	60	2	25	23	200	-8.00	4	N/R
	3	Fluvoxamine	300	1	32	27	300	-16.00	3	N/R
	4	Citalopram	70	1	27	25	25 (E/W)*	-7.00	4	N/R
	5	Clomipramine	250	2	22	27	100	23.00	5	N/R
	6	Paroxetine	60	5	35	32	300	-9.00	4	N/R
	7	Fluoxetine	80	3	25	16	300	-36.00	2	R
	8	Sertraline	200	1	18	3	50	-83.00	1	R
	9	Fluoxetine	20	1	21	20	300	-5.00	4	N/R
	10	Fluoxetine	60	1	22	17	300	-23.00	2	N/R
	11	Citalopram	60	1	32	17	300	-47.00	1	R
	12	Fluoxetine	80	1	32	14	300	-56.00	1	R
	13	Fluvoxamine	300	1	30	12	50	-60.00	1	R
	14	Fluoxetine	60	1	25	7	50	-72.00	1	R
	15	Citalopram	60	1	27	24	200	-11.00	4	N/R
	16	Fluvoxamine	300	1	24	12	150	-50.00	2	R
	17	Fluvoxamine	200	2	22	22	50	.00	4	N/R
	18	Fluvoxamine	300	2	25	22	25	-12.00	4	N/R
	19	Fluoxetine	60	2	24	25	25 (E/W)*	4.00	4	N/R
	20	Clomipramine	250	2	27	12	300	-56.00	2	R
Placebo	1	Fluvoxamine	300	2	32	25	300	-22.00	3	N/R
	2	Fluvoxamine	300	1	30	28	300	-7.00	3	N/R
	3	Fluoxetine	80	2	34	38	300	12.00	4	N/R
	4	Paroxetine	60	1	22	18	300	-18.00	1	N/R
	5	Citalopram	60	1	28	26	300	-7.00	4	N/R
	6	Fluoxetine	60	5	26	24	300	-8.00	3	N/R
	7	Fluoxetine	60	1	23	23	300	.00	4	N/R
	8	Fluoxetine	60	1	27	10	300	-63.00	1	R
	9	Fluoxetine	40	1	32	18	300	-44.00	2	R
	10	Citalopram	60	2	24	23	300	-4.00	4	N/R
	11	Citalopram	60	1	35	23	300	-34.00	2	R
	12	Fluvoxamine	300	3	22	14	300	-36.00	2	R
	13	Citalopram	60	1	28	10	50	-65.00	2	R
	14	Fluoxetine	60	1	28	4	50	-86.00	2	R
	15	Citalopram	60	1	26	19	100	-27.00	2	R
	16	Fluoxetine	60	1	27	12	100	-56.00	1	R
	17	Fluoxetine	20	1	26	18	200	-31.00	2	R
	18	Fluvoxamine	300	2	23	35	200	52.00	6	N/R
	19	Citalopram	60	2	26	9	100	-65.00	2	R
	20	Paroxetine	80	1	32	29	300	-9.00	3	N/R
	21	Fluvoxamine	300	3	31	25	100	-19.00	2	N/R

*E/W = Early withdrawal